Effects of Tofacitinib combined with Methotrexate in treatment of patients with rheumatoid arthritis
Objective:To observe effects of Tofacitinib combined with Methotrexate in treatment of patients with rheumatoid arthritis. Methods:The clinical data of 88 patients with rheumatoid arthritis admitted to this hospital from April 2021 to April 2023 were retrospectively analyzed. According to different treatment methods,they were divided into control group and observation group,44 cases in each group. The control group was treated with Methotrexate tablets,while the observation group was treated with Tofacitinib citrate tablets on the basis of that of the control group. The clinical efficacy,the pain degree[visual analogue scale (VAS)]score,the disease activity[disease activity score (DAS28)]score,the inflammatory factors[interferon-γ (IFN-γ),interleukin-6 (IL-6),interleukin-35 (IL-35),interleukin-17 (IL-17)]levels,the disease-specific indexes[soluble intercellular adhesion molecule-1 (sICAM-1),angiopoietin-like protein 2 (Angptl2)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups. Results:The total effective rate of treatment in the observation group was 100.00％ (44/44),which was higher than 86.36％ (38/44) in the control group,and the difference was statistically significant (P<0.05). The VAS and DAS28 scores of the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant (P<0.05). After the treatment,the levels of IFN-γ,IL-6 and IL-17 in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;the levels of IL-35 in the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;and the differences were statistically significant (P<0.05). The levels of sICAM-1 and Angptl2 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant (P<0.05). However,there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusions:Tofacitinib combined with Methotrexate in the treatment of the patients with rheumatoid arthritis can improve the total effective rate of treatment,improve the levels of inflammatory factors,and reduce the pain degree scores,disease activity scores and disease specific index levels. Moreover,it is superior to simple Methotrexate treatment.
万方数据
维普
